• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

A Five-year Prospective Multi-center Evaluation of Influenza Infection in Transplant Recipients

tetano

Editor, Senior Moderator
Clin Infect Dis. 2018 Apr 7. doi: 10.1093/cid/ciy294. [Epub ahead of print]
[h=1]A Five-year Prospective Multi-center Evaluation of Influenza Infection in Transplant Recipients.[/h] Kumar D[SUP]1[/SUP], Ferreira VH[SUP]1[/SUP], Blumberg E[SUP]2[/SUP], Silveira F[SUP]3[/SUP], Cordero E[SUP]4[/SUP], Perez-Romero P[SUP]4[/SUP], Aydillo T[SUP]4[/SUP], Danziger-Isakov L[SUP]5[/SUP], Limaye AP[SUP]6[/SUP], Carratala J[SUP]7[/SUP], Munoz P[SUP]8[/SUP], Montejo M[SUP]9[/SUP], Lopez-Medrano F[SUP]10[/SUP], Farinas MC[SUP]11[/SUP], Gavalda J[SUP]12[/SUP], Moreno A[SUP]13[/SUP], Levi M[SUP]14[/SUP], Fortun J[SUP]15[/SUP], Torre-Cisneros J[SUP]16[/SUP], Englund JA[SUP]17[/SUP], Natori Y[SUP]1[/SUP], Husain S[SUP]1[/SUP], Reid G[SUP]18[/SUP], Sharma TS[SUP]19[/SUP], Humar A[SUP]1[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] [h=4]Background:[/h] Seasonal influenza infection may cause significant morbidity and mortality in transplant patients. The purpose of this study was to assess the epidemiology of symptomatic influenza infection post-transplant and determine risk factors for severe disease.
[h=4]Methods:[/h] Twenty centers in the U.S., Canada and Spain prospectively enrolled solid organ transplant (SOT) or stem cell transplant (HSCT) patients with microbiologically-confirmed influenza over five consecutive years (2010-15). Demographics, microbiology data, and outcomes were collected. Serial nasopharyngeal swabs were collected at diagnosis (day 0),3,6,11,18, 28 days and quantitative PCR for influenza A was performed.
[h=4]Results:[/h] We enrolled 616 patients with confirmed influenza (477 SOT; 139 HSCT); Most infections (77.3%) were influenza A. Pneumonia at presentation was seen in 134/606(22.1%). Antiviral therapy was given to 94.1% for a median of 5 days (range 1-42). 66.5% patients were hospitalized and 11.0% required ICU care with 8.0% needing mechanical ventilation. The receipt of vaccine in the same influenza season was associated with a decrease in disease severity as determined by the presence of pneumonia (OR 0.34 (95%CI 0.21-0.55), p<0.001) and ICU admission (OR 0.49 (95%CI 0.26-0.90), p=0.023). Similarly, early antiviral treatment (within 48 hours) was associated with improved outcomes. In patients with influenza A, pneumonia, ICU admission, and not being immunized were also associated with higher viral loads at presentation (p=0.018, p=0.008, p=0.024 respectively).
[h=4]Conclusion:[/h] Annual influenza vaccination and early antiviral therapy are associated with a significant reduction in influenza-associated morbidity, and should be emphasized as strategies to improve outcomes of transplant recipients.


PMID: 29635437 DOI: 10.1093/cid/ciy294
 
Back
Top Bottom